Shots: Exicure to receive a $20M up front and will be eligible to receive ~$1B in option exercise fees and milestones along with royalties, if Ipsen exercises its option Exicure […]readmore
Tags : Exicure
Shots: Exicure to receive $25M upfront, up to $97.5/program development & regulatory milestones, ~$265/program commercial milestones, royalties on global sales of therapies developed under the collaboration and will conduct discovery […]readmore